These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2867156)

  • 1. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
    Marvola M; Kannikoski A; Taskinen J; Ottoila P
    J Pharm Pharmacol; 1985 Nov; 37(11):766-70. PubMed ID: 2867156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.
    Eichelbaum M; Dengler HJ; Somogyi A; von Unruh GE
    Eur J Clin Pharmacol; 1981 Jan; 19(2):127-31. PubMed ID: 7202472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel chewable sustained-release tablet containing verapamil hydrochloride.
    El-Gazayerly ON; Rakkanka V; Ayres JW
    Pharm Dev Technol; 2004; 9(2):181-8. PubMed ID: 15202577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
    Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation, bioavailability, and pharmacokinetics of sustained-release potassium chloride tablets.
    Senel S; Capan Y; Dalkara T; Inanç N; Hincal AA
    Pharm Res; 1991 Oct; 8(10):1313-7. PubMed ID: 1796051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
    Moreland TA; McMurdo ME; McEwen J
    Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of once-daily verapamil: comparative bioavailability of two sustained-release formulations.
    Muirhead DC; Norris RJ; Cockayne D; Hill GW
    Br J Clin Pract Suppl; 1988 Apr; 60():14-9. PubMed ID: 3151264
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preparation of verapamil hydrochloride core-in-cup tablets with double-pulsatile and multi-phasic release].
    Li CJ; Zhu JB; Yu WY
    Yao Xue Xue Bao; 2008 Jun; 43(6):652-6. PubMed ID: 18822971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
    Baviskar D; Sharma R; Jain D
    Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
    Sawicki W; Janicki S
    Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new sustained-release formulation of verapamil in the treatment of hypertension.
    Midtbo KA; Hals O; Lauve O
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific rationale and clinical implications of sustained-release formulations.
    Kellaway IW
    Br J Clin Pract Suppl; 1988 Apr; 60():9-13. PubMed ID: 3151274
    [No Abstract]   [Full Text] [Related]  

  • 17. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers.
    Xu X; Sun M; Zhi F; Hu Y
    Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of pH Modulation on Dynamic Behavior of Gel Layer and Release of Weakly Basic Drug from HPMC/Wax Matrices, Controlled by Acidic Modifiers Evaluated by Multivariate Data Analysis.
    Mašková E; Kubová K; Vysloužil J; Pavloková S; Vetchý D
    AAPS PharmSciTech; 2017 May; 18(4):1242-1253. PubMed ID: 27474035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability study of two different verapamil formulations.
    Horne C; Stenzhorn G; Blume H; Knauf H; Mutschler E
    Arch Pharm (Weinheim); 1992 Aug; 325(8):531-6. PubMed ID: 1417461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.